These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 36726477)

  • 1. Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia.
    Han AH; Burroughs CR; Falgoust EP; Hasoon J; Hunt G; Kakazu J; Lee T; Kaye AM; Kaye AD; Ganti L
    Health Psychol Res; 2022; 10(5):67898. PubMed ID: 36726477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suvorexant in the Treatment of Difficulty Falling and Staying Asleep (Insomnia).
    Berger AA; Sottosanti ER; Winnick A; Keefe J; Gilbert E; Hasoon J; Thase ME; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2022 Feb; 52(1):68-90. PubMed ID: 35342199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel class of medications, orexin receptor antagonists, in the treatment of insomnia - critical appraisal of suvorexant.
    Norman JL; Anderson SL
    Nat Sci Sleep; 2016; 8():239-47. PubMed ID: 27471419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
    Patel KV; Aspesi AV; Evoy KE
    Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
    Owen RT
    Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience.
    Matsumura T; Terada J; Yoshimura C; Koshikawa K; Kinoshita T; Yahaba M; Nagashima K; Sakao S; Tatsumi K
    Drug Des Devel Ther; 2019; 13():809-816. PubMed ID: 30880914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
    Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
    Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suvorexant for the treatment of insomnia.
    Jacobson LH; Callander GE; Hoyer D
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):711-30. PubMed ID: 25318834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2014 Dec; 68(12):1429-41. PubMed ID: 25231363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women.
    Rahman SA; Nathan MD; Wiley A; Crawford S; Cohn AY; Harder JA; Grant LK; Erickson A; Srivastava A; McCormick K; Bertisch SM; Winkelman JW; Joffe H
    Sleep; 2022 Mar; 45(3):. PubMed ID: 35022783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
    J Clin Sleep Med; 2016 Sep; 12(9):1215-25. PubMed ID: 27397664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Ivgy-May N; Snyder E; Liu K; Snavely DB; Krystal AD; Walsh JK; Benca RM; Rosenberg R; Sangal RB; Budd K; Hutzelmann J; Leibensperger H; Froman S; Lines C; Roth T; Michelson D
    Biol Psychiatry; 2016 Jan; 79(2):136-48. PubMed ID: 25526970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suvorexant: scientifically interesting, utility uncertain.
    Keks NA; Hope J; Keogh S
    Australas Psychiatry; 2017 Dec; 25(6):622-624. PubMed ID: 28994603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Suvorexant on Nocturnal Delirium in Elderly Patients with Alzheimer's Disease: A Case-series Study.
    Hanazawa T; Kamijo Y
    Clin Psychopharmacol Neurosci; 2019 Nov; 17(4):547-550. PubMed ID: 31671494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapies for sleep disturbances in dementia.
    McCleery J; Sharpley AL
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD009178. PubMed ID: 33189083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial.
    Herring WJ; Ceesay P; Snyder E; Bliwise D; Budd K; Hutzelmann J; Stevens J; Lines C; Michelson D
    Alzheimers Dement; 2020 Mar; 16(3):541-551. PubMed ID: 31944580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lemborexant, an orexin receptor antagonist sedative-hypnotic: Is it useful for insomnia in psychiatric disorders?
    Keks NA; Hope J
    Australas Psychiatry; 2022 Aug; 30(4):530-532. PubMed ID: 35491942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.
    Sun H; Palcza J; Rosenberg R; Kryger M; Siringhaus T; Rowe J; Lines C; Wagner JA; Troyer MD
    Respir Med; 2015 Mar; 109(3):416-26. PubMed ID: 25661282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-based insomnia treatment strategy using novel orexin antagonists: A review.
    Kishi T; Nishida M; Koebis M; Taninaga T; Muramoto K; Kubota N; Moline M; Sakuma K; Okuya M; Nomura I; Iwata N
    Neuropsychopharmacol Rep; 2021 Dec; 41(4):450-458. PubMed ID: 34553844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
    Michelson D; Snyder E; Paradis E; Chengan-Liu M; Snavely DB; Hutzelmann J; Walsh JK; Krystal AD; Benca RM; Cohn M; Lines C; Roth T; Herring WJ
    Lancet Neurol; 2014 May; 13(5):461-71. PubMed ID: 24680372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.